Skip to content

US · QNCX · BIOTECHNOLOGY

Quince Therapeutics, Inc. (QNCX) intrinsic value and stock valuation

$31.73as of 2026-11-21 · Mkt cap 8.41M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Quince Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values QNCX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from QNCX’s statements →

Quince Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology South San Francisco, CA 94080 quincetx.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-83.98M
20172025
Free cash flow
-$-41.78M
20172025
Total equity
-$-35.71M
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-50.43M-$-57.28M-$-34.62M-$-52.02M-$-90.32M
Net income-$-83.98M-$-56.83M-$-31.39M-$-51.66M-$-89.94M
EPSd-$-335.92M-$-258.32M-$-165.21M-$-303.88M-$-599.6M
Operating cash flow-$-41.42M-$-31.9M-$-18.29M-$-44.04M-$-62.93M
Capital expenditure-$-350K-$-260K-$-160K-$-130K-$-180K
Free cash flow-$-41.78M-$-32.16M-$-18.45M-$-44.17M-$-63.11M
Total assets$93.5M$114.5M$180.2M$103.9M$133.2M
Total debt$18.5M$14.8M$13.8M$450K$1.16M
Net debt$12.7M$8.6M-$-6.94M-$-44.13M-$-68.56M
Total equity-$-35.71M$30.2M$85.1M$100.6M$118.6M
Cash and short-term investments$17.8M$40.8M$75.1M$90.2M$106.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$140K$0.00$0.00$0.00$0.00
Gross profit-$-140K$0.00$0.00$0.00$0.00
Research and development expenses$35.4M$18.6M$9.45M$25.2M$60.8M
Selling, general and administrative expenses$15.1M$17.6M$17.7M$26M$29.5M
Other expenses-$-140K$21.1M$7.48M$820K$0.00
Operating expenses$50.3M$57.3M$34.6M$52M$90.3M
Cost and expenses$50.4M$57.3M$34.6M$52M$90.3M
Interest income$1.24M$2.93M$3.48M$1.07M$620K
Interest expense$0.00$0.00$0.00$570K$0.00
Depreciation and amortization$140K$190K$320K$200K$340K
Ebitda-$-80.62M-$-35.98M-$-26.82M-$-50.99M-$-89.6M
Operating income-$-50.43M-$-57.28M-$-34.62M-$-52.02M-$-90.32M
Total other income/expenses, net-$-30.34M$540K$3.04M$70K$370K
Income before tax-$-80.77M-$-56.74M-$-31.58M-$-51.94M-$-89.94M
Income tax expense$3.21M$90K-$-200K-$-280K$0.00
Net income-$-83.98M-$-56.83M-$-31.39M-$-51.66M-$-89.94M
Weighted average shares outstanding$250K$220K$190K$170K$150K
Weighted average diluted shares outstanding$250K$220K$190K$170K$150K
Balance sheet
20252024202320222021
Cash and short-term investments$17.8M$40.8M$75.1M$90.2M$106.8M
Net receivables$3.62M$880K$990K$0.00$1.13M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$22.9M$44M$77.4M$93.8M$111.7M
Property, plant and equipment, net$1.05M$810K$620K$680K$1.43M
Goodwill and intangible assets$67.8M$60.1M$81.3M$5.9M$0.00
Long-term investments$80K$80K$80K$3.58M$19.9M
Total non-current assets$70.6M$70.4M$102.8M$10.2M$21.6M
Total assets$93.5M$114.5M$180.2M$103.9M$133.2M
Accounts payable$2.22M$2.9M$2.03M$570K$4.91M
Short-term debt$18.1M$100K$60K$450K$740K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$43.2M$7.28M$9.57M$3.07M$14.2M
Long-term debt$330K$14.7M$13.8M$0.00$420K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$86M$77.1M$85.6M$250K$420K
Capital lease obligations$120K$490K$320K$450K$1.16M
Total liabilities$129.2M$84.3M$95.1M$3.32M$14.6M
Common stock$60K$40K$40K$40K$30K
Retained earnings-$-460.45M-$-376.47M-$-319.64M-$-288.26M-$-236.6M
Accumulated other comprehensive income (loss)$5.75M-$-40K$3.05M-$-290K-$-80K
Total equity-$-35.71M$30.2M$85.1M$100.6M$118.6M
Total investments$12M$34.7M$54.4M$49.2M$57M
Total debt$18.5M$14.8M$13.8M$450K$1.16M
Net debt$12.7M$8.6M-$-6.94M-$-44.13M-$-68.56M
Cash flow statement
20252024202320222021
Net income-$-83.98M-$-56.83M-$-31.39M-$-51.66M-$-89.94M
Depreciation and amortization$140K$190K$320K$200K$340K
Stock-based compensation$5.11M$4.75M$5.22M$16.6M$29.9M
Change in working capital$12.8M-$-480K$1.98M-$-9.83M-$-4.26M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-940K$930K-$-290K-$-5.94M$1.36M
Net cash provided by operating activities-$-41.42M-$-31.9M-$-18.29M-$-44.04M-$-62.93M
Investments in property, plant and equipment-$-350K-$-260K-$-160K-$-130K-$-180K
Acquisitions, net$0.00$0.00-$-2.12M$10.6M-$-58.95M
Net cash used for investing activities$23.2M$21.9M-$-5.76M$18M$59M
Common stock issued$17.9M$230K$150K$610K$6.81M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$17.9M-$-4.78M$140K$710K$6.81M
Net change in cash-$-400K-$-14.54M-$-23.83M-$-25.14M$2.88M
Cash at end of period$5.81M$6.21M$20.8M$44.6M$69.7M
Operating cash flow-$-41.42M-$-31.9M-$-18.29M-$-44.04M-$-62.93M
Capital expenditure-$-350K-$-260K-$-160K-$-130K-$-180K
Free cash flow-$-41.78M-$-32.16M-$-18.45M-$-44.17M-$-63.11M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Quince Therapeutics, Inc.

        Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.

        CEO
        Dirk Thye
        Employees
        38
        Beta
        1.40

        Explore

        Frequently asked questions

        What is the intrinsic value of Quince Therapeutics, Inc. (QNCX)?

        InvestorsCraft does not currently publish an intrinsic value for QNCX. How the IC value is calculated.

        Is QNCX undervalued?

        InvestorsCraft does not publish an undervaluation signal for QNCX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.